Cite
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
MLA
Escobar, Carlos, et al. “SGLT2 Inhibitors and GLP1 Agonists Administered without Metformin Compared to Other Glucose‐lowering Drugs in Patients with Type 2 Diabetes Mellitus to Prevent Cardiovascular Events: A Systematic Review.” Diabetic Medicine, vol. 38, no. 3, Mar. 2021, pp. 1–9. EBSCOhost, https://doi.org/10.1111/dme.14502.
APA
Escobar, C., Barrios, V., Cosín, J., Gámez Martínez, J. M., Huelmos Rodrigo, A. I., Ortíz Cortés, C., Torres Llergo, J., Requeijo, C., Solà, I., & Martínez Zapata, M. J. (2021). SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Diabetic Medicine, 38(3), 1–9. https://doi.org/10.1111/dme.14502
Chicago
Escobar, Carlos, Vivencio Barrios, Juan Cosín, José María Gámez Martínez, Ana Isabel Huelmos Rodrigo, Carolina Ortíz Cortés, Javier Torres Llergo, Carolina Requeijo, Ivan Solà, and Mª José Martínez Zapata. 2021. “SGLT2 Inhibitors and GLP1 Agonists Administered without Metformin Compared to Other Glucose‐lowering Drugs in Patients with Type 2 Diabetes Mellitus to Prevent Cardiovascular Events: A Systematic Review.” Diabetic Medicine 38 (3): 1–9. doi:10.1111/dme.14502.